AstraZeneca’s (AZN) “Overweight” Rating Reaffirmed at JPMorgan Chase & Co.

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reissued by equities research analysts at JPMorgan Chase & Co. in a report issued on Thursday, January 18th. They presently have a GBX 5,500 ($77.12) price target on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 15.30% from the company’s current price.

Other equities analysts have also issued reports about the stock. Deutsche Bank reaffirmed a “buy” rating and set a GBX 5,600 ($78.52) target price on shares of AstraZeneca in a research report on Wednesday, October 11th. Sanford C. Bernstein set a GBX 5,780 ($81.04) target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Monday, September 25th. Societe Generale reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, September 21st. BNP Paribas set a GBX 5,800 ($81.32) target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Monday, September 25th. Finally, Kepler Capital Markets raised their target price on shares of AstraZeneca from GBX 5,200 ($72.91) to GBX 5,250 ($73.61) and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of GBX 5,211.65 ($73.07).

AstraZeneca (LON AZN) traded down GBX 75 ($1.05) during trading on Thursday, reaching GBX 4,770 ($66.88). 4,070,758 shares of the company were exchanged, compared to its average volume of 1,980,000. The stock has a market cap of $60,260.00 and a price-to-earnings ratio of 2,805.88. AstraZeneca has a 12 month low of GBX 4,260 ($59.73) and a 12 month high of GBX 5,520 ($77.40).

In other news, insider Philip A. J. Broadley bought 415 shares of the stock in a transaction on Friday, February 2nd. The stock was bought at an average cost of GBX 4,846 ($67.95) per share, for a total transaction of £20,110.90 ($28,198.12).

TRADEMARK VIOLATION WARNING: This article was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://ledgergazette.com/2018/02/11/astrazeneca-azn-receives-overweight-rating-from-jpmorgan-chase-co.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply